← Back
Physiology and Medicine

Faster Proxy Biomarkers

Identify and validate robust biomarkers and surrogate endpoints to serve as effective proxies in clinical trials, enabling faster and more informative evaluations. This is especially important for aging (e.g., as proposed by the Norn Group).

Resources (4)

Data Gaps that Bottleneck Aging Biomarker Discovery
Whitepapers and Essays
Evaluation of Biomarkers and Surrogate Endpoint in Chronic Disease
Whitepapers and Essays
ARPA-H Program: PROSPR - Proactive Solutions for Prolonging Resilience
Funding Program
ASBMR SABRE Team Submits Full Qualification Plan to FDA for Approval of Bone Mineral Density as a Surrogate Endpoint for Future Trials of New Anti-Osteoporosis Drugs
Research and Reviews

R&D Gaps (1)

Clinical Trials are Inefficient, Slow and Scarce

Physiology and Medicine
Clinical trial designs are often inefficient, resulting in high costs, lengthy timelines, and suboptimal patient outcomes. Innovative trial designs and decision-support tools are required to streamline the clinical evaluation process and accelerate therapeutic development.
Physiology and Medicine
10